ABSTRACT
Background Actigraphy can clarify useful patient-centered outcomes for quantification of physical activity in the “real-world” setting.
Methods To characterize the relationship of actigraphy outputs with “in-laboratory” measures of cardiopulmonary function and respiratory symptoms in pre-COPD, we obtained actigraphy data for 8 hours/day for 5 consecutive days a week before in-laboratory administration of respiratory questionnaires, PFT, and CPET to a subgroup of subjects participating in the larger study of the health effects of exposure to secondhand tobacco smoke who had air trapping but no spirometric obstruction (pre-COPD). Using machine learning approaches, we identified the most relevant actigraphy predictors and examined their associations with symptoms, lung function, and exercise outcomes.
Results Sixty-one subjects (age=66±7years; BMI=24±3kg/m2; FEV1/FVC=0.75±0.05; FEV1=103±17%predicted) completed the nested study. In the hierarchical cluster analysis, the activity, distance, and energy domains of actigraphy, including moderate to vigorous physical activity, were closely correlated with each other, but were only loosely associated with spirometric and peak exercise measures of oxygen consumption, ventilation, oxygen-pulse, and anaerobic threshold (VO2AT), and were divergent from symptom measures. Conversely, the sedentary domain clustered with respiratory symptoms, air trapping, airflow indices, and ventilatory efficiency. In Regression modeling, sedentary domain was inversely associated with baseline lung volumes and tidal breathing at peak exercise, while the activity domains were associated with VO2AT. Respiratory symptoms and PFT data were not associated with actigraphy outcomes.
Discussion Outpatient actigraphy can provide information for “real-world” patient-centered outcomes that are not captured by standardized respiratory questionnaires, lung function, or exercise testing. Actigraphy activity and sedentary domains inform of distinct outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov Identifier: NCT02797275
Funding Statement
This work was supported by: 1.Flight Attendant Medical Research Institute (012500WG to WMG and CIA190001 to MA). 2.California Tobacco-Related Disease Research Program (TRDRP) (T29IR0715 to MA). 3.The Department of Veterans Affairs Airborne Hazard and Burn Pit Center of Excellence (to MA). 4.Radboud University School of Medicine Scholarship (to JG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of California San Francisco (UCSF) Institutional Review Board (IRB) and the San Francisco VA Medical Center Committee on Research and Development approved the study protocols.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email Addresses: JC: jianhong.chen{at}ucsf.edu
LW: weldemichael.lemlem{at}gmail.com
BG: briangiang{at}gwmail.gwu.edu
JG: jeroengeerts{at}msn.com
SZ: Siyang.zeng{at}ucsf.edu
WCC: Wendy.Ching{at}ucsf.edu
MN: mynishihama{at}gmail.com
WMG: warren.gold{at}ucsf.edu
MA: mehrdad.arjomandi{at}ucsf.edu
Discussion section has been extensively revised. Visual abstract has been added.
Data Availability
Data are available upon reasonable request.